Drugs / Penehyclidine
Penehyclidine
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 44 trials | ||||||
| Phase 4 | NCT06624696 | Nov 2024 → Aug 2026 overdue | hypersensitivity reaction disease | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 4 | NCT04054479 | Jul 2019 | — | The First Affiliated Hospital with Nanjing Medical University | Completed | No outcome recorded |
| Phase 4 | NCT03868709 | Mar 2019 → Dec 2021 | — | Peking University First Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02644876 | Sep 2015 → Nov 2018 | — | Peking University First Hospital | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07519226 | May 2024 → Mar 2026 | — | Lihua Wen | Completed | No outcome recorded |
| — | NCT04454866 | Jul 2020 → Mar 2021 | — | Peking University First Hospital | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02202239 Background | Sep 2014 → Aug 2015 | — | Zhujiang Hospital | Unknown | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Penehyclidine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04054479 ↗ |
| Known as | penehyclidine hydrochloride | “receive either inhaling penehyclidine hydrochloride (PHC, a dose of 0.05 mg/kg, diluted and mixed with normal saline to a total volume of 5 ml) or identical volumes and colour...” PMID 41928281 ↗ Apr 20263“the M1/M3-selective antagonist penehyclidine hydrochloride could more effectively reverse pediatric microcirculatory dysfunction” NCT07519226 ↗ “Penehyclidine hydrochloride is a new anticholinergic agent, which selectively blocks M1 and M3, but not M2 receptors.” NCT02644876 ↗ “Penehyclidine hydrochloride is a new anticholinergic agent, which selectively blocks M1 and M3 receptors.” NCT03868709 ↗ |
| Known as | Penequine | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594416 ↗ |
| Known as | PHC | “receive either inhaling penehyclidine hydrochloride (PHC, a dose of 0.05 mg/kg, diluted and mixed with normal saline to a total volume of 5 ml) or identical volumes and colour...” PMID 41928281 ↗ Apr 2026 |
| Action | Inhibit | “Penehyclidine is a long-acting anticholinergic agent which selectively blocks M1 and M3 receptors.” PMID 29183393 ↗ Nov 2017 |
| Modality | Small molecule | — CHEMBL4594416 ↗ |
| Route | Inhaled | “Penehyclidine inhalation will be administered by inhalation” NCT02644876 ↗ |